Difficulty: Medium
Average Score: 64%
Practice
The characteristic feature of phenytoin pharmacokinetics is
Correct answer
C
Rationale
Phenytoin is a widely used antiepileptic drug with unique pharmacokinetic properties. The characteristic feature of phenytoin pharmacokinetics that sets it apart is capacity-limited metabolism saturating at higher therapeutic concentration range, which is option C.
This means that as the plasma concentration of phenytoin increases, the rate of metabolism becomes constant and no longer increases with higher doses. This is important clinically because it leads to the phenomenon of zero-order kinetics, where a constant amount of drug is metabolized per unit time, regardless of the drug concentration in the body. This can result in nonlinear dose-response relationships and a narrow therapeutic window for phenytoin.
Now, let's discuss why the other options are incorrect:
A) High first-pass metabolism: This is not a characteristic feature of phenytoin. First-pass metabolism occurs in the liver before the drug reaches systemic circulation, which is not a defining aspect of phenytoin metabolism.
B) Nonsaturation kinetics of metabolism: This is incorrect because phenytoin metabolism does exhibit saturation kinetics, as explained earlier, where the metabolic rate becomes constant at higher concentrations.
D) Extrahepatic metabolism: Phenytoin is primarily metabolized in the liver by cytochrome P450 enzymes, so extrahepatic metabolism is not a characteristic feature of phenytoin pharmacokinetics.
Understanding these pharmacokinetic properties of phenytoin is crucial for nurses and healthcare professionals when administering and monitoring this drug in patients with epilepsy. It helps in optimizing dosage regimens and avoiding toxicity or subtherapeutic effects.
This means that as the plasma concentration of phenytoin increases, the rate of metabolism becomes constant and no longer increases with higher doses. This is important clinically because it leads to the phenomenon of zero-order kinetics, where a constant amount of drug is metabolized per unit time, regardless of the drug concentration in the body. This can result in nonlinear dose-response relationships and a narrow therapeutic window for phenytoin.
Now, let's discuss why the other options are incorrect:
A) High first-pass metabolism: This is not a characteristic feature of phenytoin. First-pass metabolism occurs in the liver before the drug reaches systemic circulation, which is not a defining aspect of phenytoin metabolism.
B) Nonsaturation kinetics of metabolism: This is incorrect because phenytoin metabolism does exhibit saturation kinetics, as explained earlier, where the metabolic rate becomes constant at higher concentrations.
D) Extrahepatic metabolism: Phenytoin is primarily metabolized in the liver by cytochrome P450 enzymes, so extrahepatic metabolism is not a characteristic feature of phenytoin pharmacokinetics.
Understanding these pharmacokinetic properties of phenytoin is crucial for nurses and healthcare professionals when administering and monitoring this drug in patients with epilepsy. It helps in optimizing dosage regimens and avoiding toxicity or subtherapeutic effects.